

03rd November, 2018

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2018

The presentation on unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2018 to be made to analysts is enclosed for your records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: As above



Q2 & H1 FY 2018-19



Consolidated Revenues for Q2 2018-19

(` Crore)

Particulars	Q2 1819	Q2 1718	Gr%
India (Incl Unichem)	816	607	34%
US	393	255	54%
Brazil	147	120	23%
Germany	251	209	20%
Other	167	128	30%
Others (Incl contract Mfg.)	120	98	22%
Total	1,894	1,417	34%



Consolidated Revenues for H1 2018-19

(₹ Crore)

Particulars	H1 1819	H1 1718	Gr%
India (Incl Unichem)	1,645	1,071	54%
US	727	527	38%
Brazil	316	301	5%
Germany	503	399	26%
Other	325	248	31%
Others (Incl contract Mfg.)	250	233	7%
Total	3,766	2,779	36%

